Corcept Therapeutics (CORT) AI Stock Analysis

• Market Cap: $8.17B
• Dividend Yield: N/A
• Average Volume (3M): 769.51K
• Price to Earnings (P/E): 88.8
• Beta (1Y): 0.50
• Revenue Growth: 17.92%
• EPS Growth: -26.13%
• Country: US
• Employees: 500
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.16
• Shares Outstanding: 105,188,220
• 10 Day Avg. Volume: 594,954
• 30 Day Avg. Volume: 769,515
• PEG Ratio: 1.15
• Price to Book (P/B): 7.65
• Price to Sales (P/S): 7.71
• P/FCF Ratio: 26.55
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 12.83
• Enterprise Value/Gross Profit: 13.07
• Enterprise Value/Ebitda: 131.25
• 1Y Price Target: $135.33
• Price Target Upside: 68.57% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.96
• Revenue Forecast (FY): $819.25M

• Rating: 72 Outperform
• Price Target: $85.00 ▲(5.88% Upside)

Corcept Therapeutics' overall stock score is driven by strong financial health and promising growth prospects in its pipeline, particularly in hypercortisolism and oncology. However, high valuation and declining net income pose risks. The technical indicators suggest neutral momentum, and unresolved patent litigation adds uncertainty.

Positive Factors

Revenue Growth

The consistent revenue growth indicates strong market demand and effective sales strategies, enhancing long-term financial stability and market position.

Hypercortisolism Business Expansion

Significant growth in the hypercortisolism segment underscores Corcept's leadership in this niche market, bolstering its competitive advantage and revenue potential.

Pipeline Advancements

Advancements in the pipeline with upcoming PDUFA dates highlight potential for new product launches, driving future revenue growth and market expansion.

Negative Factors

Decline in Net Income

A significant decline in net income suggests challenges in cost management or pricing pressures, which could impact profitability and financial health.

Patent Litigation Uncertainty

Unresolved patent litigation poses a risk to Korlym's market exclusivity, potentially affecting future revenue streams and competitive positioning.

Pharmacy Capacity Constraints

Capacity constraints with the previous pharmacy vendor could disrupt supply chain efficiency and customer satisfaction, affecting sales and growth.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

How the Company Makes Money

Corcept Therapeutics generates revenue primarily through the sales of Korlym, its approved drug for Cushing's syndrome. The company earns income from product sales to healthcare providers and patients, and it may also receive royalties or milestones from partnerships related to its drug development pipeline. In addition, Corcept has engaged in collaborations with other pharmaceutical companies, which can provide funding and resources for research and development, thereby contributing to its overall revenue. These partnerships may involve sharing in the profits of jointly developed drugs or receiving upfront payments and milestones based on development progress.

Corcept Therapeutics Financial Statement Overview

Summary

Corcept Therapeutics demonstrates strong financial health with high profitability and a solid balance sheet. While revenue growth is steady, the decline in profit margins and free cash flow growth may pose challenges. The company’s low leverage and effective equity utilization are key strengths, providing stability in a competitive biotechnology industry.

Income Statement

Corcept Therapeutics shows strong profitability with a high gross profit margin of 98.19% TTM, indicating efficient cost management. However, the net profit margin has decreased to 14.19% TTM from 20.70% in the previous year, reflecting a decline in net income relative to revenue. Revenue growth is modest at 3.50% TTM, suggesting stable but slow expansion. EBIT and EBITDA margins have also decreased, indicating potential challenges in operational efficiency.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.01 TTM, indicating minimal leverage and financial risk. Return on equity is strong at 20.10% TTM, showcasing effective use of equity to generate profits. The equity ratio of 76.73% TTM highlights a solid capital structure with a significant portion of assets financed by equity.

Cash Flow

Operating cash flow remains healthy, but the free cash flow has decreased by 9.83% TTM, suggesting potential cash management issues. The operating cash flow to net income ratio is 0.95 TTM, indicating that cash generation is slightly lagging behind net income. The free cash flow to net income ratio is nearly 1, showing that most of the net income is converted into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	741.17M	675.04M	482.38M	401.86M	365.98M	353.87M
Gross Profit	727.78M	664.16M	475.89M	396.47M	360.70M	348.29M
EBITDA	72.46M	138.29M	108.32M	113.89M	127.95M	130.44M
Net Income	105.19M	139.73M	106.14M	101.42M	112.51M	106.01M
Balance Sheet
Total Assets	823.61M	840.55M	621.52M	583.43M	423.76M	571.73M
Cash, Cash Equivalents and Short-Term Investments	421.68M	383.33M	368.22M	431.67M	223.53M	440.70M
Total Debt	6.36M	6.94M	151.00K	1.14M	526.00K	2.55M
Total Liabilities	191.71M	160.96M	114.81M	81.59M	47.95M	48.39M
Stockholders Equity	631.90M	679.59M	506.70M	501.84M	375.81M	523.34M
Cash Flow
Free Cash Flow	162.57M	195.90M	126.90M	119.91M	167.42M	150.73M
Operating Cash Flow	162.85M	198.07M	127.04M	120.32M	167.89M	151.97M
Investing Cash Flow	17.24M	-177.60M	90.91M	-114.33M	136.13M	-119.26M
Financing Cash Flow	-193.71M	-28.35M	-148.72M	-17.28M	-302.59M	12.21M

Corcept Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 80.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CORT, the sentiment is Positive. The current price of 80.28 is above the 20-day moving average (MA) of 75.75, above the 50-day MA of 78.26, and above the 200-day MA of 71.72, indicating a bullish trend. The MACD of 0.64 indicates Negative momentum. The RSI at 58.48 is Neutral, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CORT.

Corcept Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CORT	72 Outperform	$8.17B	88.79	16.47%	―	17.92%	-26.13%
JAZZ	63 Neutral	$10.99B	―	-9.06%	―	4.14%	-179.96%
AXSM	55 Neutral	$7.62B	―	-275.50%	―	65.83%	28.50%
RYTM	52 Neutral	$7.26B	―	-240.36%	―	54.92%	28.47%
RVMD	52 Neutral	$14.24B	―	-60.76%	―	-100.00%	-44.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LEGN	47 Neutral	$5.21B	―	-22.60%	―	74.91%	31.54%

Corcept Therapeutics Corporate Events

Corcept Therapeutics’ Earnings Call Highlights Growth Amid Challenges

Corcept Therapeutics’ recent earnings call painted a picture of robust revenue growth and a promising pipeline, particularly in the areas of hypercortisolism and oncology. However, the call also highlighted some challenges, including a notable decline in net income and ongoing patent litigation issues that could impact future operations.

Corcept Therapeutics Reports Q3 Growth and Expands Oncology Programs

Corcept Therapeutics, a commercial-stage biopharmaceutical company, focuses on the discovery and development of medications that modulate the effects of cortisol to treat severe disorders, including endocrinologic, oncologic, metabolic, and neurologic conditions.

Corcept Therapeutics Reports Q3 2025 Revenue Growth

On November 4, 2025, Corcept Therapeutics announced its financial results for the third quarter of 2025, reporting a revenue increase to $207.6 million from $182.5 million in the same quarter of 2024. The company has expanded its oncology development programs, including new studies in various cancers, and is approaching significant clinical milestones, such as the New Drug Application for relacorilant in hypercortisolism and platinum-resistant ovarian cancer. Despite a decrease in net income compared to the previous year, Corcept is optimistic about meeting the increasing demand for its products and advancing its clinical trials.

The most recent analyst rating on (CORT) stock is a Buy with a $83.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics Ends Distribution Agreement with Optime

On October 10, 2025, Corcept Therapeutics announced the termination of its Distribution Services Agreement with Optime Care, effective January 8, 2026. This decision follows a previous notification in June 2025, where Corcept exercised its rights to end Optime’s exclusivity in providing pharmacy services for its medications, impacting the company’s distribution strategy and potentially altering its market dynamics.

The most recent analyst rating on (CORT) stock is a Buy with a $82.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics Board Member Resigns, Continues as Consultant

On October 10, 2025, Gillian Cannon, Ph.D., resigned from the Board of Directors of Corcept Therapeutics Incorporated. Her resignation was not due to any disagreements with the company. The company has expressed gratitude for her contributions. In conjunction with her resignation, Dr. Cannon will continue to provide consulting services to the Board until the 2026 stockholders meeting, receiving a monthly fee and maintaining her stock options’ vesting schedule.

The most recent analyst rating on (CORT) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics’ New Drug Application Accepted by FDA

On September 10, 2025, Corcept Therapeutics announced that the FDA has accepted its New Drug Application for relacorilant, intended for treating patients with platinum-resistant ovarian cancer. This acceptance, based on positive Phase 2 and 3 trial results, marks a significant step towards offering a new treatment option for this challenging condition, with the FDA assigning a PDUFA date of July 11, 2026. Relacorilant, which has shown improved progression-free and overall survival rates without increasing safety risks, could potentially redefine treatment for this form of cancer.

The most recent analyst rating on (CORT) stock is a Buy with a $79.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.

Corcept Therapeutics’ Miricorilant Study: A Potential Game-Changer for Liver Disease Treatment

Corcept Therapeutics is currently recruiting for a Phase 1 clinical study titled ‘Evaluation of Miricorilant on Liver Fat in Patients With MASLD.’ The study aims to assess the effect of Miricorilant on hepatic lipids in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH). This research is significant as it targets a prevalent liver condition with limited treatment options.

Corcept Therapeutics’ MOMENTUM Study: A Closer Look at Hypercortisolism in Resistant Hypertension

Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension in the United States of America (MOMENTUM).’ The study aims to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN). This research is significant as it could reveal important insights into the relationship between eHC and rHTN, potentially leading to better management strategies for affected patients.

Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant

Corcept Therapeutics is conducting a Phase 1 study titled ‘Evaluation of Miricorilant on Liver Fat in Patients With MASLD.’ The study aims to assess the effect of Miricorilant on hepatic lipids in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH). This research is significant as it targets a condition linked to metabolic disorders, offering potential therapeutic advancements.

Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension

Corcept Therapeutics is conducting a study titled ‘Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)’ to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) in the United States. This study aims to enroll approximately 1,000 patients across 45 sites, focusing on identifying eHC in a specific patient population, which could have significant implications for treatment approaches in resistant hypertension.

Corcept Therapeutics Advances in Ovarian Cancer Treatment with New Phase 2 Study

Corcept Therapeutics is currently recruiting participants for a Phase 2 clinical study titled A Phase 2 Study of Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA). The study aims to evaluate the efficacy and safety of an intermittent dosing regimen of relacorilant combined with nab-paclitaxel and bevacizumab in patients with advanced ovarian cancer, highlighting its potential significance in improving treatment outcomes.